Peter Ferdinandy
Overview
Explore the profile of Peter Ferdinandy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
314
Citations
8135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hernandez-Resendiz S, Vilskersts R, Aluja D, Andreadou I, Bencsik P, Dambrova M, et al.
Basic Res Cardiol
. 2025 Mar;
PMID: 40072549
Although many cardioprotective interventions have been shown to limit infarct size (IS), in preclinical animal studies of acute myocardial ischemia/reperfusion injury (IRI), their clinical translation to patient benefit has been...
2.
Tamargo J, Agewall S, Ambrosio G, Borghi C, Cerbai E, Dan G, et al.
Eur Heart J Cardiovasc Pharmacother
. 2025 Mar;
PMID: 40058879
Despite substantial advances in cardiovascular pharmacotherapy and devices in recent years, prevention and treatment of many cardiovascular diseases (CVD) remain limited, thus reflecting the need for more effective and safer...
3.
Onodi Z, Riba P, Ferdinandy P, Gorbe A, Varga Z
BMC Med Educ
. 2025 Feb;
25(1):327.
PMID: 40022050
Background: The flipped classroom (FC) approach has demonstrated efficacy in enhancing the learning process, including within higher education contexts such as medical education. Recently, FC has emerged as potential alternative...
4.
Topouzis S, Papapetropoulos A, Alexander S, Cortese-Krott M, Kendall D, Martemyanov K, et al.
Br J Pharmacol
. 2025 Feb;
182(7):1416-1445.
PMID: 39971274
In the past year, the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) authorised 53 novel drugs. While the...
5.
Barbieri M, Abate A, Balogh O, Petervari M, Ferdinandy P, Agg B, et al.
Drug Saf
. 2025 Feb;
PMID: 39918677
Background: Safety signals for potential drug-induced adverse events (AEs) typically emerge from multiple data sources, primarily spontaneous reporting systems, despite known limitations. Increasingly, real-world data from sources such as electronic...
6.
Plesz S, Adlan L, Buki A, Makra N, Ligeti B, Agg B, et al.
Prog Neuropsychopharmacol Biol Psychiatry
. 2025 Jan;
137:111276.
PMID: 39880276
Comorbidities between gastrointestinal diseases and psychiatric disorders have been widely reported, with the gut-brain axis implicated as a potential biological basis. Thus, dysbiosis may play an important role in the...
7.
Curtis M, Alexander S, Cortese-Krott M, Kendall D, Martemyanov K, Mauro C, et al.
Br J Pharmacol
. 2025 Jan;
182(7):1413-1415.
PMID: 39865712
No abstract available.
8.
Gergely T, Kovacs T, Kovacs A, Toth V, Sayour N, Morotz G, et al.
ESC Heart Fail
. 2024 Nov;
PMID: 39535377
Background: Cardiac remodelling, a crucial aspect of heart failure, is commonly investigated in preclinical models by quantifying cardiomyocyte cross-sectional area (CSA) and microvascular density (MVD) via histological methods, such as...
9.
Sayour N, Kucsera D, Alhaddad A, Toth V, Gergely T, Kovacs T, et al.
Basic Res Cardiol
. 2024 Nov;
120(1):207-223.
PMID: 39516409
Despite accumulating data on underlying mechanisms, the influence of sex and prevalent cardio-metabolic co-morbidities on the manifestation and severity of immune checkpoint inhibitor (ICI)-induced cardiotoxicity has not been well defined....
10.
Nemeth K, Kestecher B, Ghosal S, Bodnar B, Kittel A, Hambalko S, et al.
Br J Pharmacol
. 2024 Nov;
181(23):4733-4749.
PMID: 39491825
In recent years, various approaches have been undertaken to eliminate lipoproteins co-isolated with extracellular vesicles, as they were initially regarded as contaminating entities. However, novel discoveries are reshaping our perspective....